Ying Tian

954 total citations · 1 hit paper
22 papers, 686 citations indexed

About

Ying Tian is a scholar working on Physiology, Psychiatry and Mental health and Pharmacology. According to data from OpenAlex, Ying Tian has authored 22 papers receiving a total of 686 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Physiology, 7 papers in Psychiatry and Mental health and 6 papers in Pharmacology. Recurrent topics in Ying Tian's work include Alzheimer's disease research and treatments (11 papers), Dementia and Cognitive Impairment Research (7 papers) and Cholinesterase and Neurodegenerative Diseases (6 papers). Ying Tian is often cited by papers focused on Alzheimer's disease research and treatments (11 papers), Dementia and Cognitive Impairment Research (7 papers) and Cholinesterase and Neurodegenerative Diseases (6 papers). Ying Tian collaborates with scholars based in United States, China and United Kingdom. Ying Tian's co-authors include Samantha Budd Haeberlein, Spyros Chalkias, Stephen Salloway, Fiona Forrestal, Frederik Barkhof, Priya Singhal, Guanfang Wang, Derk D. Purcell, Joyce Suhy and Kimberly Umans and has published in prestigious journals such as Neurology, American Journal of Public Health and Journal of Affective Disorders.

In The Last Decade

Ying Tian

21 papers receiving 671 citations

Hit Papers

Amyloid-Related Imaging A... 2021 2026 2022 2024 2021 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
    2021 411 citations Stephen Salloway, Spyros Chalkias et al. JAMA Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ying Tian United States 10 429 167 165 138 105 22 686
Patrick Burkett United States 2 280 0.7× 102 0.6× 103 0.6× 97 0.7× 74 0.7× 4 415
Patrícia Regina Manzine Brazil 18 430 1.0× 159 1.0× 123 0.7× 271 2.0× 96 0.9× 37 819
Kristen Morris United States 6 439 1.0× 153 0.9× 88 0.5× 143 1.0× 106 1.0× 11 570
Brian A. Willis United States 16 554 1.3× 308 1.8× 301 1.8× 161 1.2× 115 1.1× 48 905
Aidan Power United States 11 282 0.7× 176 1.1× 175 1.1× 127 0.9× 61 0.6× 25 554
Alessandra Bizzarro Italy 18 349 0.8× 204 1.2× 154 0.9× 216 1.6× 88 0.8× 40 886
Dev Mehta United States 7 255 0.6× 106 0.6× 87 0.5× 170 1.2× 86 0.8× 19 573
Karen C. Holdridge United States 14 426 1.0× 476 2.9× 144 0.9× 66 0.5× 83 0.8× 29 826
Hana Florian United States 8 203 0.5× 219 1.3× 256 1.6× 97 0.7× 61 0.6× 20 502
Robert A. Swarm United States 11 498 1.2× 203 1.2× 245 1.5× 189 1.4× 71 0.7× 26 1.0k

Countries citing papers authored by Ying Tian

Since Specialization
Citations

This map shows the geographic impact of Ying Tian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ying Tian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ying Tian more than expected).

Fields of papers citing papers by Ying Tian

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ying Tian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ying Tian. The network helps show where Ying Tian may publish in the future.

Co-authorship network of co-authors of Ying Tian

This figure shows the co-authorship network connecting the top 25 collaborators of Ying Tian. A scholar is included among the top collaborators of Ying Tian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ying Tian. Ying Tian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Tianle, Ying Tian, & Brian A. Millen. (2025). Surrogate Endpoints in Drug Development: A Review of Statistical and Regulatory Perspectives and Applications. Wiley Interdisciplinary Reviews Computational Statistics. 17(1). 1 indexed citations
2.
3.
Cummings, Jeffrey L., Sharon Cohen, Holly M. Brothers, et al.. (2025). Evaluation of cognitive, functional, and behavioral effects observed in EMERGE, a phase 3 trial of aducanumab in people with early Alzheimer's disease. Alzheimer s & Dementia. 21(6). e70224–e70224. 3 indexed citations
4.
Chen, Tianle, John O’Gorman, Carmen Castrillo‐Viguera, et al.. (2024). Results from the long‐term extension of PRIME: A randomized Phase 1b trial of aducanumab. Alzheimer s & Dementia. 20(5). 3406–3415. 11 indexed citations
5.
Wang, Zixian, et al.. (2024). Correlation between physical exercise levels, depressive symptoms, and sleep quality in college students: Evidence from electroencephalography. Journal of Affective Disorders. 369. 789–799. 10 indexed citations
6.
7.
Tian, Ying, et al.. (2023). The relationship between physical activity and diabetes in middle-aged and elderly people. Medicine. 102(6). e32796–e32796. 5 indexed citations
8.
9.
10.
Salloway, Stephen, Spyros Chalkias, Frederik Barkhof, et al.. (2021). Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. JAMA Neurology. 79(1). 13–13. 411 indexed citations breakdown →
11.
Zhang, Mingyan, et al.. (2021). Core outcome set for stable angina pectoris in traditional Chinese medicine (COS-SAP-TCM). 1(1). 39–48. 10 indexed citations
12.
Guo, Dong, et al.. (2021). Efficacy and safety of Shugan Jieyu capsule in the treatment of essential hypertension with insomnia, anxiety or depression. Medicine. 100(8). e24856–e24856. 9 indexed citations
13.
Rajagovindan, Raj, Tianle Chen, Ying Tian, et al.. (2021). Subgroup analyses of the amyloid PET substudies from EMERGE and ENGAGE, phase 3 clinical trials evaluating aducanumab in patients with early Alzheimer’s disease. Alzheimer s & Dementia. 17(S9). 1 indexed citations
14.
15.
Haeberlein, Samantha Budd, Christian von Hehn, Ying Tian, et al.. (2020). Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s disease. Alzheimer s & Dementia. 16(S9). 57 indexed citations
16.
Liu‐Seifert, Hong, Jennifer Schumi, Xiaopeng Miao, et al.. (2020). Disease Modification in Alzheimer’s Disease: Current Thinking. Therapeutic Innovation & Regulatory Science. 54(2). 396–403. 16 indexed citations
17.
Liu‐Seifert, Hong, Jennifer Schumi, Xiaopeng Miao, et al.. (2019). Disease Modification in Alzheimer’s Disease: Current Thinking. Therapeutic Innovation & Regulatory Science. 3593143741–3593143741. 1 indexed citations
18.
Hehn, Christian von, Philipp von Rosenstiel, Ying Tian, et al.. (2019). Baseline Characteristics From ENGAGE and EMERGE: Two Phase 3 Studies to Evaluate Aducanumab in Patients With Early Alzheimer’s Disease (P4.1-001). Neurology. 92(15_supplement). 10 indexed citations
19.
Haeberlein, Samantha Budd, John O’Gorman, Ping-Chun Chiao, et al.. (2017). Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease.. PubMed. 4(4). 255–263. 74 indexed citations
20.
Viglietta, Vissia, John O’Gorman, Leslie Williams, et al.. (2016). Randomized, Double-Blind, Placebo-Controlled Studies to Evaluate Treatment with Aducanumab (BIIB037) in Patients with Early Alzheimer’s Disease: Phase 3 Study Design (S1.003). Neurology. 86(16_supplement). 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Patrick Burkett Breakdown of academic impact, for papers by Patrícia Regina Manzine Breakdown of academic impact, for papers by Kristen Morris Breakdown of academic impact, for papers by Brian A. Willis Breakdown of academic impact, for papers by Aidan Power Breakdown of academic impact, for papers by Alessandra Bizzarro Breakdown of academic impact, for papers by Dev Mehta Breakdown of academic impact, for papers by Karen C. Holdridge Breakdown of academic impact, for papers by Hana Florian Breakdown of academic impact, for papers by Robert A. Swarm
Rankless by CCL
2026